BIM Stock Overview
Develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BIM from our risk checks.
bioMérieux S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €109.60 |
| 52 Week High | €111.10 |
| 52 Week Low | €88.95 |
| Beta | 0.19 |
| 11 Month Change | 4.18% |
| 3 Month Change | 21.04% |
| 1 Year Change | 22.87% |
| 33 Year Change | 12.99% |
| 5 Year Change | n/a |
| Change since IPO | -11.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIM | AT Medical Equipment | AT Market | |
|---|---|---|---|
| 7D | 1.4% | 5.1% | 0.6% |
| 1Y | 22.9% | 21.4% | 7.3% |
Return vs Industry: BIM exceeded the Austrian Medical Equipment industry which returned 19.2% over the past year.
Return vs Market: BIM exceeded the Austrian Market which returned 6.9% over the past year.
Price Volatility
| BIM volatility | |
|---|---|
| BIM Average Weekly Movement | 3.1% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in AT Market | 6.1% |
| 10% least volatile stocks in AT Market | 1.8% |
Stable Share Price: BIM has not had significant price volatility in the past 3 months.
Volatility Over Time: BIM's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1963 | 13,696 | Pierre Boulud | www.biomerieux.com |
bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry.
bioMérieux S.A. Fundamentals Summary
| BIM fundamental statistics | |
|---|---|
| Market cap | €12.87b |
| Earnings (TTM) | €411.30m |
| Revenue (TTM) | €3.81b |
31.3x
P/E Ratio3.4x
P/S RatioIs BIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIM income statement (TTM) | |
|---|---|
| Revenue | €3.81b |
| Cost of Revenue | €1.69b |
| Gross Profit | €2.12b |
| Other Expenses | €1.71b |
| Earnings | €411.30m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.49 |
| Gross Margin | 55.72% |
| Net Profit Margin | 10.81% |
| Debt/Equity Ratio | 10.1% |
How did BIM perform over the long term?
See historical performance and comparison